Roflumilast Daliresp、罗氟司特片、迪开舒

Roflumilast tablets are a selective phosphodiesterase-4 (PDE4) inhibitor primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD), particularly for patients with concurrent chronic bronchitis and frequent exacerbations. They improve respiratory function by inhibiting the inflammatory response, reducing airway obstruction and mucus secretion. Use as directed by your doctor and do not adjust the dose on your own.

Mechanism of Action
Inhibition of the PDE4 enzyme: Reduces the release of inflammatory mediators (such as TNF-α and IL-8), alleviating airway inflammation.
Improves lung function: Long-term use can reduce the frequency of COPD exacerbations and slow disease progression.
Indications
Adult COPD patients: Indicated for patients with a history of chronic bronchitis and at least one exacerbation in the past year.
Adjunctive Therapy: Often used in combination with other bronchodilators (such as long-acting β2-agonists).
Usage and Dosage
Usual dose: One tablet (500 μg) orally once daily, either on an empty stomach or with food. Special Populations: Contraindicated in patients with severe liver impairment; elderly patients do not require dose adjustment, but should be closely monitored for adverse reactions.
Common Adverse Reactions
Gastrointestinal Reactions: Diarrhea, nausea, and decreased appetite (often occur initially and resolve with treatment).
Weight Loss: Monitor weight regularly; seek medical evaluation if weight loss persists.
Psychiatric Symptoms: Insomnia and anxiety are rare; severe cases require discontinuation.
Precautions
Contraindications: Contraindicated in patients with moderate to severe liver impairment and pregnant or lactating women.
Drug Interactions: Avoid coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole); dose adjustment may be required.
Monitoring Indicators: Regularly monitor liver function, weight, and mental status during treatment.
Medical Instructions
Roflumilast is a prescription drug and should be used only after evaluation by a healthcare professional. If severe diarrhea, persistent weight loss, or mental disturbances occur, discontinue the drug immediately and seek medical attention. Patients should avoid increasing or decreasing the dosage on their own or mixing it with other medications. During treatment, follow-up lung function tests and lifestyle management (such as smoking cessation) are required.